Bleeding Disorders
Conference Coverage
Large cohort study: Bevacizumab safe, effective for severe HHT bleeds
Bevacizumab was effective for severe HHT-related epistaxis and GI bleeds, leading to "significant and striking improvements" on a variety of...
Conference Coverage
SPK-8011 AAV-mediated hemophilia A therapy shows stability, durability
Conference Coverage
Liver biopsies show persistent FVIII after gene therapy for hemophilia A
“This was very exciting to see ... [n]ot only were we able to detect vector genomes more than 2 years post-dose, there seems to be quite a bit of...
From the Journals
Heavy menstrual bleeding difficult to control in young patients with inherited platelet disorders
Consensus and a broadly effective treatment for heavy menstrual bleeding was not found among the patients with inherited platelet function...
From the Journals
Subcutaneous hep A vaccination as effective as intramuscular for bleeding disorder patients
Conference Coverage
Onyx stent meets DAPT performance goal in bleeding-risk patients
A zotarolimus-eluting coronary stent met its FDA-set performance goal in high-bleeding-risk patients on dual antiplatelet therapy for 1 month.
Feature
Pandemic strains blood supply for COVID-19 and noninfected patients
From the Journals
Cardiovascular problems already apparent in children with hemophilia A
...
News
FDA approves recombinant treatment for hemophilia A or B with inhibitors
The new treatment is made using milk from transgenic rabbits.
Conference Coverage
Early results with ‘optimized’ gene therapy in hemophilia A
Conference Coverage
Gene therapy effective in hemophilia B patients with neutralizing antibodies